Association between atrial fibrillation and heart failure patient reported outcomes across the ejection fraction spectrum - 07/06/24
ABSTRACT |
Background |
Atrial fibrillation (AF) is common in patients with heart failure (HF) and is associated with worse clinical outcomes. We evaluated the relationship between AF and longitudinal changes in health-related quality of life (HRQoL) measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) in both HF with preserved (HFpEF) and reduced ejection fraction (HFrEF).
Methods |
This is a post-hoc analysis of the TOPCAT and HF-ACTION trials. The effect of AF on KCCQ overall summary scores (OSS), in both trials, was examined using a mixed effects regression model. Patients were divided into 3 groups according to AF status at baseline: patients with a history of AF but no AF detected on ECG at enrollment (Hx AF group), patients with history of AF and AF detected on ECG at enrollment (ECG AF group) and patients with post-randomization new-onset AF (New AF group).
Results |
In TOPCAT, among 1,710 patients with KCCQ data available, AF was associated with a significantly lower KCCQ-OSS (-3.98; 95% CI −7.21: −0.74) at 48 months, with a significant AF status by time interaction (P = .03). In HF-ACTION, among 1,814 patients with available KCCQ data, AF was associated with a significantly lower KCCQ-OSS (-3.67; 95% CI −6.21: −1.41) at 24 months but there was no significant AF status by time interaction. In both trials, the type of AF was not associated with significant changes in KCCQ-OSS score.
Conclusion |
Ιn patients with both HFpEF and HFrEF, AF was independently associated with worse HRQoL measured by KCCQ.
Le texte complet de cet article est disponible en PDF.Plan
| Dr. Anna Gundlund, MD, PhD served as Guest Editor for this manuscript. |
Vol 273
P. 61-71 - juillet 2024 Retour au numéro
Article précédent
- Association between visit frequency, continuity of care, and pharmacy fill adherence in heart failure patients
- Carine E. Hamo, Amrita Mukhopadhyay, Xiyue Li, Yaguang Zheng, Ian M. Kronish, Rumi Chunara, John Dodson, Samrachana Adhikari, Saul Blecker
- Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2)
- Ana Navas-Acien, Regina M. Santella, Bonnie R. Joubert, Zhen Huang, Yuliya Lokhnygina, Francisco Ujueta, Irina Gurvich, Nancy J. LoIacono, Filippo Ravalli, Cynthia D. Ward, Jeffery M. Jarrett, Alfonsina De Leon Salazar, Robin Boineau, Teresa L.Z. Jones, Daniel B. Mark, Jonathan D. Newman, David M. Nathan, Kevin J. Anstrom, Gervasio A. Lamas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?